Abstract
The authors describe CMV retinitis in resource-poor settings and suggest possibilities for management.
MeSH terms
-
AIDS-Related Opportunistic Infections / complications
-
AIDS-Related Opportunistic Infections / diagnosis
-
AIDS-Related Opportunistic Infections / drug therapy*
-
AIDS-Related Opportunistic Infections / epidemiology
-
AIDS-Related Opportunistic Infections / immunology
-
Acquired Immunodeficiency Syndrome / drug therapy*
-
Acquired Immunodeficiency Syndrome / epidemiology
-
Acquired Immunodeficiency Syndrome / immunology
-
Africa South of the Sahara / epidemiology
-
Anti-Retroviral Agents / economics
-
Anti-Retroviral Agents / therapeutic use*
-
Antiviral Agents / economics
-
Antiviral Agents / therapeutic use*
-
Asia, Southeastern / epidemiology
-
Blindness / epidemiology
-
Blindness / immunology
-
Blindness / prevention & control*
-
Blindness / virology
-
CD4 Lymphocyte Count
-
Cytomegalovirus Retinitis / complications
-
Cytomegalovirus Retinitis / diagnosis
-
Cytomegalovirus Retinitis / drug therapy*
-
Cytomegalovirus Retinitis / epidemiology
-
Cytomegalovirus Retinitis / immunology
-
Developing Countries
-
Disease Outbreaks*
-
Drug Costs
-
Ganciclovir / analogs & derivatives*
-
Ganciclovir / economics
-
Ganciclovir / therapeutic use
-
Health Services Accessibility
-
Humans
-
Mass Screening
-
Ophthalmoscopy
-
Program Development
-
Treatment Outcome
-
Valganciclovir
Substances
-
Anti-Retroviral Agents
-
Antiviral Agents
-
Valganciclovir
-
Ganciclovir